Second-line Chemotherapy in Castration Resistant Prostate Cancer

Inclusion Criteria: * Metastatic castration resistant prostate cancer * Disease progression during or after docetaxel-containing regimen for mCRPC * Surgical or medical castration * WHO performance status \< 2 * Age \> 18 years * Adequate bone marrow, liver and renal functions: Hematology: * neutrophils \> 1.5 x 109/ l * hemoglobin \> 100 g/l * platelets \> 100 x 109/l Hepatic and renal functions: * total bilirubin \<1 x ULN * ALAT and ASAT \< 2.5 x ULN, alkaline phosphate \<6 x ULN.In the presence of extensive bone disease, alkaline phosphate \> 6 x ULN is accepted * creatinine \< 1.5 x ULN (ie NCI CTC-AE grade \< 1) Exclusion Criteria: * Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment * Prior therapy with radioisotopes * Other malignant disease (except superficial non-melanoma skin cancer) within the past 5 years * Serious liver disease * History of severe hypersensitivity reaction (grade \> 3) to polysorbate 80 containing drugs * Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who already are on these treatments) * Other serious illness or medical condition: * Serious cardiac disease; ischemic or thromboembolic cardiac disease, pulmonary emboli, cardiac infarction within 12 months * Active infection * Active peptic ulcer, uncontrolled diabetes mellitus or other contraindications for the use of corticosteroids * Auto-immune disease (lupus, scleroderma, rheumatoid polyarthritis) * Active grade \> 2 polyneuropathy